1 Publications
0 with at least 1 overall serious concern assessment
1 Assessments
0 Serious · 1 Some · 0 No · 0 N/A
| Publication | Total | Overall Assessment | Actions | |||
|---|---|---|---|---|---|---|
| Serious | Some | No | N/A | |||
Anti-CD38 monoclonal antibody CM313 for primary immune thrombocytopenia: multicentre, randomised, placebo controlled, phase 2 trial 10.1136/bmj-2025-084314 | 1 | — | 1 | — | — | View |